TRUQAP becomes the first targeted treatment approved for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, marking a major step forward in precision medicine
Wilmington, Delaware, 15 June 2026 – A major advancement in prostate cancer treatment has arrived with the approval of TRUQAP (capivasertib) in the United States. Developed by AstraZeneca, the therapy has been cleared for use in combination with abiraterone and prednisone for adults diagnosed with PTEN-deficient metastatic hormone-sensitive prostate cancer, an aggressive form of the disease that has historically been difficult to treat. The approval represents the first targeted treatment specifically designed for this patient group.
Prostate cancer remains one of the most commonly diagnosed cancers among men worldwide. While many patients respond well to existing therapies, those with PTEN-deficient tumors often face faster disease progression and poorer outcomes. PTEN is a tumor suppressor gene that helps regulate cell growth. When the gene is lost or deficient, cancer cells can grow and spread more aggressively. Around one in four patients with metastatic hormone-sensitive prostate cancer is believed to have PTEN deficiency.
The approval follows encouraging results from the Phase III CAPItello 281 clinical trial, which evaluated the effectiveness of capivasertib when added to standard treatment. Researchers found that the combination reduced the risk of disease progression or death by 19 percent compared with standard therapy alone. The study also demonstrated a meaningful improvement in the time patients lived without their cancer worsening.
What makes this approval especially significant is the move toward precision medicine in prostate cancer. Rather than treating all patients in the same way, doctors can now identify individuals with PTEN-deficient tumors through approved diagnostic testing and offer a therapy specifically targeted to the biology of their cancer. This personalized approach aims to improve outcomes while helping patients receive treatments most likely to benefit them.
Medical experts view the approval as an important milestone because it addresses a major unmet need. Patients with PTEN-deficient metastatic hormone-sensitive prostate cancer often experience rapid disease progression and limited treatment options. The availability of a targeted therapy could help extend disease control and potentially improve the quality of life for many patients facing this diagnosis.
The approval also highlights the growing role of biomarker testing in cancer care. Healthcare providers are increasingly using genetic and molecular information to guide treatment decisions. By identifying biomarkers such as PTEN deficiency, physicians can better match patients with therapies that target specific cancer pathways. This trend is expected to continue as researchers develop more personalized cancer treatments in the coming years.
TRUQAP is already approved for certain types of advanced breast cancer, and this latest decision expands its role into prostate cancer treatment. The drug works by blocking AKT, a protein involved in cell growth and survival. By targeting this pathway, the therapy helps slow cancer progression and enhances the effectiveness of existing treatment combinations.
The US Food and Drug Administration also approved a companion diagnostic test that helps identify eligible patients with PTEN-deficient prostate cancer. This ensures that the treatment reaches those most likely to benefit from it, reinforcing the importance of precision oncology in modern healthcare.
As cancer research continues to evolve, the approval of TRUQAP for PTEN-deficient metastatic hormone-sensitive prostate cancer offers renewed optimism for patients, physicians, and caregivers. By combining targeted science with personalized treatment strategies, the therapy represents another step toward improving outcomes in one of the world’s most common cancers.